# Pentixapharm Reports International Data Supporting Phase 3 PANDA Trial

- URL: https://stocks.freetheai.org/news/pentixapharm-reports-international-data-supporting-phase-3-panda-trial-e01561
- Published: 2026-10-19T06:30:04Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [XETR:PTP](https://stocks.freetheai.org/symbols/XETR-PTP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Pentixapharm Holding AG (PTP) presented new international evidence supporting its diagnostic imaging candidate, PentixaFor PET, at the EANM 2026 medical conference. The findings back the company's Phase 3 PANDA trial evaluating primary aldosteronism. The U.S. Food and Drug Administration cleared the study in June 2026 and granted it Fast Track designation in July 2026. Preparations for U.S. clinical site activation and trial launch are ongoing. Shares of Pentixapharm rose 1.10% to 1.84 EUR following the update.

The Phase 3 trial aims to demonstrate whether PentixaFor PET can reduce reliance on invasive adrenal vein sampling, a standard procedure in diagnosing primary aldosteronism. Demonstrating diagnostic accuracy could expand market adoption and establish a simpler standard of care. Additionally, Pentixapharm is preparing a Phase I/II trial called PENTHERA to advance its theranostic oncology pipeline.

Investors will monitor the activation of U.S. trial sites, patient enrollment milestones, and eventual Phase 3 data readouts to assess the candidate's path toward regulatory approval.

## Key points

- Pentixapharm presented international evidence supporting PentixaFor PET at the EANM 2026 conference.
- The FDA cleared the Phase 3 PANDA trial in June 2026 and granted Fast Track designation in July 2026.
- PentixaFor PET aims to reduce the need for invasive adrenal vein sampling in primary aldosteronism.
- Pentixapharm is also planning a Phase I/II trial named PENTHERA in oncology.

## Questions and answers

### What is Pentixapharm's Phase 3 PANDA trial evaluating?

The Phase 3 PANDA trial evaluates PentixaFor PET for primary aldosteronism, aiming to reduce the need for invasive adrenal vein sampling procedures.

### Has the FDA approved Pentixapharm's PANDA trial?

The FDA cleared the Phase 3 PANDA study in June 2026 and granted Fast Track status in July 2026, allowing preparations for U.S. trial launch to proceed.